Patient-Focused Drug Development for Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Heralds a New Chapter in Patient Advocacy

The SADS Foundation hosted a virtual externally-led patient-focused drug development meeting (EL-PFDD) with the US FDA on June 20, 2023. The meeting was designed to educate the FDA and other key stakeholders, including patient advocates, drug developers, and health care providers on the patient’s perspective about the challenges of living with ARVC/D with the limited therapies available today